Lake Forest, CA, June 3, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that the Company is supporting ArunA Biomedical’s (“ArunA”) cryogenic shipments of stem cell kits.
ArunA Biomedical, Inc. is a privately held life science tools company dedicated to advancing drug discovery and basic research through the development and commercialization of platform technology products and services for the stem cell research community. ArunA's patented platform cellular technology provides an adherent, monolayer cell culture system in a simple format suited for rapid results. ArunA’s stem cell kits offer an efficient and economical alternative to less informative drug discovery and research tools.
Cryoport’s comprehensive cryogenic logistics solutions will support the cryogenic shipment of ArunA’s stem cell kits to the research community. The Company’s global network allows ArunA’s products to reach their diverse worldwide customer base without compromising the integrity of the product and enables more efficient results through greater safety and speed of delivery.
Steven Stice, Ph.D., Chairman and Chief Scientific Officer of ArunA Biomedical, commented, “Researchers depend on our stem cell kits to be consistent and reliable. In turn, we rely on Cryoport’s validated cryogenic logistics solutions to maintain those standards during shipment. We look forward to working with Cryoport to help us service the global research community to efficiently address their high development costs and long timelines.”
Mr. Jerrell Shelton, Cryoport’s Chief Executive Officer, stated, “We are excited to work with ArunA Biomedical with the progression of stem cell research. It is difficult and costly to maintain human stem cells. ArunA’s products eliminate this burdensome task and with our best-in-class cryogenic solutions, we help them place these cells into the hands of researchers who may not otherwise have the capability or the resources to produce them.”
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.Investor Contacts:
Todd Fromer / Garth Russell
firstname.lastname@example.org / email@example.com
P: 1 212-682-6300